KR920011482A - 뇌 발작을 치료하는데 있어서의 헵타스티그민의 용도 - Google Patents
뇌 발작을 치료하는데 있어서의 헵타스티그민의 용도 Download PDFInfo
- Publication number
- KR920011482A KR920011482A KR1019910023605A KR910023605A KR920011482A KR 920011482 A KR920011482 A KR 920011482A KR 1019910023605 A KR1019910023605 A KR 1019910023605A KR 910023605 A KR910023605 A KR 910023605A KR 920011482 A KR920011482 A KR 920011482A
- Authority
- KR
- South Korea
- Prior art keywords
- heptastigmine
- treating brain
- brain attacks
- pharmaceutical composition
- group
- Prior art date
Links
- RRGMXBQMCUKRLH-CTNGQTDRSA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-heptylcarbamate Chemical compound C12=CC(OC(=O)NCCCCCCC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C RRGMXBQMCUKRLH-CTNGQTDRSA-N 0.000 title claims description 5
- 210000004556 brain Anatomy 0.000 title claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 내지 제2도는 정맥내 투여된 0.5, 1.0 및 3.0mg/kg의 용량에 대한 헵타스티그민(heptastigmine)의 용량-효과 연구 결과를 도시한 것이다.
Claims (4)
- 뇌발작 치료용 약제학적 조성물을 제조하는데 있어서의 헵타스티그민(heptastigmine)의 용도.
- 제1항에 있어서, 헵타스티그민이 타르트레이트, 시트레이트 및 말레에이트로 이루어진 그룹 중에서 선택된 가용성 염 형태임을 특징으로 하는 용도.
- 헵타스티그민과 약리학적으로 허용되고 상용되는 용매 및 희석제로 이루어진 뇌발작 치료용 약제학적 조성물.
- 제3항에 있어서, 헵타스티그민이 타르트레이트, 시트레이트 및 말레에이트로 이루어진 그룹 중에서 선택된 가용성 염의 형태이고, 용매 및 희석제가 생라학적 용액 및 중류수로 이루어진 그룹 중에서 선택됨을 특징으로 하는 약제학적 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT02251390A IT1246050B (it) | 1990-12-21 | 1990-12-21 | Impiego dell'eptastigmina nella terapia dell'ictus cerebrale. |
| IT22513A/90 | 1990-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR920011482A true KR920011482A (ko) | 1992-07-24 |
Family
ID=11197279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019910023605A KR920011482A (ko) | 1990-12-21 | 1991-12-20 | 뇌 발작을 치료하는데 있어서의 헵타스티그민의 용도 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0492383B1 (ko) |
| JP (1) | JPH04308529A (ko) |
| KR (1) | KR920011482A (ko) |
| AT (1) | ATE136776T1 (ko) |
| CA (1) | CA2058228A1 (ko) |
| DE (1) | DE69118847T2 (ko) |
| ES (1) | ES2085411T3 (ko) |
| IE (1) | IE914463A1 (ko) |
| IT (1) | IT1246050B (ko) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100908068B1 (ko) * | 2008-12-31 | 2009-07-15 | 주식회사 비케이티 | 대리석 석판, 대리석 석판 가공장치 및 그 가공방법 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1199076B (it) * | 1984-03-01 | 1988-12-30 | Consiglio Nazionale Ricerche | Derivati della fisostigmina con proprieta'di inibizione della aceticolinesterasi e relativo procedimento di produzione |
-
1990
- 1990-12-21 IT IT02251390A patent/IT1246050B/it active IP Right Grant
-
1991
- 1991-12-18 EP EP91121676A patent/EP0492383B1/en not_active Expired - Lifetime
- 1991-12-18 ES ES91121676T patent/ES2085411T3/es not_active Expired - Lifetime
- 1991-12-18 AT AT91121676T patent/ATE136776T1/de active
- 1991-12-18 DE DE69118847T patent/DE69118847T2/de not_active Expired - Fee Related
- 1991-12-19 IE IE446391A patent/IE914463A1/en not_active Application Discontinuation
- 1991-12-20 CA CA002058228A patent/CA2058228A1/en not_active Abandoned
- 1991-12-20 KR KR1019910023605A patent/KR920011482A/ko not_active Application Discontinuation
- 1991-12-20 JP JP3354447A patent/JPH04308529A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100908068B1 (ko) * | 2008-12-31 | 2009-07-15 | 주식회사 비케이티 | 대리석 석판, 대리석 석판 가공장치 및 그 가공방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| IT9022513A1 (it) | 1992-06-21 |
| IT1246050B (it) | 1994-11-07 |
| ES2085411T3 (es) | 1996-06-01 |
| IT9022513A0 (it) | 1990-12-21 |
| DE69118847D1 (de) | 1996-05-23 |
| DE69118847T2 (de) | 1996-09-05 |
| CA2058228A1 (en) | 1992-06-22 |
| ATE136776T1 (de) | 1996-05-15 |
| JPH04308529A (ja) | 1992-10-30 |
| EP0492383B1 (en) | 1996-04-17 |
| IE914463A1 (en) | 1992-07-01 |
| EP0492383A1 (en) | 1992-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2203653C2 (ru) | Использование r-энантиомера n-пропаргил-1-аминоиндана, его солей и композиции, содержащие их | |
| KR930019655A (ko) | 종양치료 조성물 및 치료방법 | |
| KR890011590A (ko) | 안지오스타틴 | |
| KR920002144A (ko) | 아연 l-카르노신 염 또는 이의 착화합물을 유효성분으로 함유하는 염증성 장질환 예방 및 치료제 | |
| KR900701261A (ko) | 비만증 치료방법 | |
| KR830002327A (ko) | 약학적 제제 | |
| KR910009256A (ko) | 식욕감소를 위한 조성물 및 그 방법 | |
| KR910019618A (ko) | 발기부전증 치료용 제약 조성물 | |
| RU2004135078A (ru) | Травяная молекула как потенциальное противолейкозное лекарственное средство | |
| KR960000247A (ko) | 사이클로스포린a 함유 조성물 및 그의 제조방법 | |
| KR900005978A (ko) | 키니딘, 아르테미시닌 및 이의 유도체를 사용한 항말라리아 조성물 및 치료방법 | |
| KR870008886A (ko) | 2-알콕시-n-(1-아자바이사이클로 [2,2,2] 옥트-3-일)벤즈아미드 및 티오벤즈아미드 | |
| KR890003391A (ko) | 칼슘 보충제 | |
| KR920019350A (ko) | 자기면역질환요법을 위한 약제조성물 | |
| KR920000326A (ko) | 사람에 있어서 몰핀 및 동족체의 진통 효과에 대한 내성 발생을 방지하기 위한 gm₁모노시알로강글리오사이드 및 이의 내부 에스테르 유도체의 용도 | |
| KR920011482A (ko) | 뇌 발작을 치료하는데 있어서의 헵타스티그민의 용도 | |
| KR900011461A (ko) | 트립스타틴을 유효성분으로 하는 치료제 | |
| KR910009270A (ko) | 15-케토-프로스타글란딘 화합물을 이용한 심기능장애의 치료방법 | |
| KR930002322A (ko) | 피라졸 유도체 | |
| KR870008885A (ko) | 2-알콕시-n(1-아자비사이클로 [2,2,2] 옥트-3-일) 벤즈 아미드-n-옥사이드를 사용하여 구토증을 억제하는 방법 | |
| EP0737476A3 (en) | A pharmaceutical preparation containing a 3-(2H)-furanone derivative for prevention and/or treatment of cataracts | |
| RU98103500A (ru) | Применение агонистов или антагонистов p2-пуриноцепторов для предупреждения цитотоксичности, вызываемой глютаматом | |
| KR880700805A (ko) | 기능성 유기 염기를 주제로 하는 뇌질환 치료용 제약 조성물 | |
| KR890001540A (ko) | 심부전증 치료제 | |
| KR900017599A (ko) | 종양 치료용 약학 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |